CD38 and Miyoshi myopathy: CD38 is a surface ectoenzyme with NAD+ase activity, which is highly expressed on malignant plasma cells: this feature makes it an exploitable target for anti-MM therapies, as demonstrated by the clinical successes of anti-CD38 MoAbs.